| This week's sponsor is Premier Research. | |  | Discovering the Great Potential of Immuno-Oncology Drugs
Immuno-modulating agents have been around a long time, but for limited uses. New immuno-oncology pathways promise big advances against a wider range of cancers. Register now for our May 23 webinar. Premier Research. It's what we do. Best. |
Featured Story | Tuesday, May 2, 2017  Novartis has licensed CAR-T patents from bluebird bio and Celyad. The agreements give Novartis the nonexclusive right to use intellectual property related to bluebird’s lentiviral vector platform and Celyad’s off-the-shelf CAR-T technology.
|
|
|
| This week's sponsor is Sensors Expo & Conference 2017. | |  | |
Top Stories | Tuesday, May 2, 2017 It was only six months ago, in a unique matchup, that venture capital firms Atlas and Third Rock came together in a $48.5 million Series A to create and launch Magenta Therapeutics; now, the upstart has added more cash, a new drug and a key collab for its Series B as it looks to waste no time boosting its clinical work. |
|
|
| Tuesday, May 2, 2017 Alongside its first-quarter financials today, Pfizer also sneaked in details of its “discontinued projects,” which includes meds from its CV and metabolism pipeline and from its neuroscience unit. |
|
|
Monday, April 24, 2017 It’s a critical tradeoff for life. Our bodies use sugar and fat from the food we consume to produce energy in our cells’ mitochondria, the internal powerhouses that give us the energy we need for all our vital functions. | Tuesday, May 2, 2017 Sunesis Pharmaceuticals has been forced to concede defeat in its bid to bring vosaroxin to the E.U. market for acute myeloid leukemia, in a near carbon copy of what happened with the FDA two years ago. |
|
|
| Tuesday, May 2, 2017 CureVac has hired Daniel Menichella as CEO of its Boston-based subsidiary. The appointment gives the mRNA specialist and Moderna rival a dealmaker last seen helping Bamboo Therapeutics to a $645 million (€591 million) takeover by Pfizer. |
|
|
| Monday, May 1, 2017 Scientists at Sanford Burnham have identified the mechanism that causes muscle cells to stop regenerating as people age. This knowledge could lead to methods to slow—but not stop—the decline in muscle mass and function as people get older. |
|
|
| Monday, May 1, 2017 A jury in Philadelphia has awarded $20 million in damages to a plaintiff who claimed that her pelvic mesh implant, made by J&J’s Ethicon unit, failed and caused her injury. |
|
|
| Monday, May 1, 2017 AstraZeneca is officially on the board with checkpoint inhibitor Imfinzi, which nabbed its first FDA approval Monday. The British pharma giant picked up an accelerated green light in urothelial carcinoma, and with it, it becomes the third Big Pharma player to enter the advanced bladder cancer space with a PD-1/PD-L1 inhibitor. |
|
|
| This week's sponsor is J.P. Morgan Private Bank. | |  | How Pre-Transaction Planning Can Maximize Your Wealth
You've worked hard to build a successful healthcare business. To reap the rewards of a sale, merger, recap or IPO, be sure you maximize the value of your equity interests with careful pre-transaction planning. Learn how J.P. Morgan Private Bank can help you protect your wealth. Read the article. |
| | | Stealth BioTherapeutics has revealed the start of its phase 1/2 study of SBT-20, a drug that works by restoring the properties of dysfunctional mitochondria, for early stage Huntington's disease. Release Altor BioScience Corporation has been given an FDA "Fast Track" tag for its IL-15 agonist complex, ALT-803, in combo with Bacillus Calmette-Guérin, for patients with bladder cancer. Statement Concert Pharmaceuticals has kick-started a phase 2a test for CTP-543 in alopecia areata, a disorder in which the immune system attacks hair follicles and can lead to complete hair loss, with topline data expected in around a year. Release | |
|
Resources Presented By: Covance The ICH GCP E6 guideline has been revised to address the complexities associated with today’s clinical trials, and this concise white paper will help you understand the recent guideline changes. Learn how use of risk-based monitoring can help you comply with the guidelines and achieve efficiency in clinical trial design, implementation and reporting. Sponsored By: Veeva To thrive in a fiercely competitive market, life sciences companies need to set themselves apart by designing and executing the best trial and successfully deliver drugs to market first. Learn how a modern EDC can help. Sponsored By Reprints Desk Puzzled by Scientific Literature Access? Here is your guide for navigating knowledge management’s twists and turns! If yours is a small- or medium-sized biopharma business, we can help you putting the pieces together. Learn the secrets of top knowledge management experts who will show you how to search, discover, acquire and manage knowledge in new ways. Presented By: Covance The recent evolution of immunotherapies and their potential applications have greatly impacted patients’ options for effective oncology treatments. These advances have been powered in part by the use of biomarkers, companion diagnostics (CDx) and complementary diagnostics. Read the white paper. Sponsored By: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Sponsored By: DocuSign The patients who rely on your scientific leadership are expecting more. Sponsored By: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. |
|
